T
34.69
-0.04 (-0.12%)
| Penutupan Terdahulu | 34.73 |
| Buka | 34.70 |
| Jumlah Dagangan | 1,596,475 |
| Purata Dagangan (3B) | 2,255,988 |
| Modal Pasaran | 3,103,794,944 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.10 |
| Harga / Jualan (P/S) | 6.99 |
| Harga / Buku (P/B) | 42.39 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | -82.88% |
| Margin Operasi (TTM) | -52.21% |
| EPS Cair (TTM) | -2.78 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 97.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,220.07% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | -160.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -239.23 M |
| Pulangan Atas Aset (ROA TTM) | -23.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -422.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Travere Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 113.30% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (HC Wainwright & Co., 35.49%) | Beli |
| Median | 35.00 (0.89%) | |
| Rendah | 25.00 (Stifel, -27.93%) | Pegang |
| Purata | 36.40 (4.93%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 30.63 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Nov 2025 | 47.00 (35.49%) | Beli | 35.41 |
| 19 Sep 2025 | 47.00 (35.49%) | Beli | 24.85 | |
| Piper Sandler | 04 Nov 2025 | 35.00 (0.89%) | Pegang | 34.13 |
| TD Cowen | 31 Oct 2025 | 40.00 (15.31%) | Beli | 35.16 |
| Stifel | 12 Sep 2025 | 25.00 (-27.93%) | Pegang | 23.47 |
| Wells Fargo | 11 Sep 2025 | 35.00 (0.89%) | Beli | 25.00 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CLINE CHRISTOPHER R. | - | 35.19 | -20,000 | -703,800 |
| Jumlah Keseluruhan Kuantiti Bersih | -20,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -703,800 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 35.19 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CLINE CHRISTOPHER R. | Pegawai | 01 Dec 2025 | Jual automatik (-) | 20,000 | 35.19 | 703,800 |
| CLINE CHRISTOPHER R. | Pegawai | 01 Dec 2025 | Pelaksanaan pilihan | 20,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |